title: Expression of multidrug resistance membrane transporter (Pgp) and p53 protein in canine mammary tumours.
abstract: The aim of this study was to determine the expression rate of P-glycoprotein (Pgp), a multidrug resistance marker and the p53 tumour-suppressor protein in canine mammary tumours. A total of 30 tumours were examined in parallel to patient history. The tumours were allotted to four groups: tubulopapillar carcinomas, complex carcinomas, benign tumours, and other malignant tumours. A monoclonal mouse antibody (C494) was used for the immunohistochemical evaluation of Pgp and a polyclonal rabbit antibody for p53. We found that the intact ductal epithelium and connective tissue showed pronounced Pgp expression. The most intensive staining was detected in tubulopapillar carcinomas for both Pgp and p53. The expression rate of Pgp and p53 differed significantly between tubulopapillar carcinoma and complex carcinoma, and between tubulopapillar carcinoma and benign mammary tumour, respectively. The expressions of Pgp and p53 highly correlated statistically; therefore, both can determine malignancy in a similar manner. In the case of tubulopapillar carcinomas, more relapsed tumours occurred than in relation to complex carcinomas and other malignant tumours. Pgp expression rate was proportional to the probability of the tumour becoming recidivant postoperatively, as well. These results suggest that routine evaluation of Pgp expression in canine mammary tumours may be prognostically helpful.
authors.affiliation: Veterinary Haematology and Oncology Centre Bolgárkertész u. 31 H-1148 Budapest Hungary.
authors.forename: Zsófia
authors.initials: Z
authors.lastname: Koltai
authors.affiliation: Szent István University Department and Clinic of Internal Medicine, Faculty of Veterinary Science Budapest Hungary Veterinary Haematology and Oncology Centre Bolgárkertész u. 31 H-1148 Budapest Hungary.
authors.forename: Péter
authors.initials: P
authors.lastname: Vajdovich
keywords: Canine; P-glycoprotein (Pgp); immunohistochemistry; mammary tumours; multidrug resistance (MDR); p53; prognostic factors; therapy resistance